ArticleEuropean heart journal. Case reports2026
Combined pulsed field ablation and left atrial appendage occlusion in a patient with persistent atrial fibrillation and adenomyosis-related menorrhagia: case report and 1-year follow-up.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulsed field ablation (PFA) is an emerging modality for atrial fibrillation management, offering rapid pulmonary vein isolation and the possibility of the left atrial posterior wall ablation. Combining PFA with left atrial appendage occlusion (LAAO) represents a holistic strategy for managing heart rhythm abnormalities and minimizing stroke risk, particularly in patients with high thromboembolic and bleeding risks. Case summary: We present a case of a 52-year-old woman with persistent atrial fibrillation, recent percutaneous coronary intervention, and a history of adenomyosis-related menorrhagia, exacerbated by the use of dual antithrombotic therapy. She underwent a single-session PFA and LAAO. The procedure was uncomplicated. At three-month follow-up, imaging confirmed appropriate device placement and complete closure. Anticoagulation was discontinued at three months, and the patient remained asymptomatic at 1-year follow-up while on single antiplatelet therapy. Discussion: This case highlights the feasibility and safety of combining PFA and LAAO in a high-risk patient and underscores the potential for broader adoption in selected populations. Larger studies are needed to evaluate long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.